论文部分内容阅读
目的 :比较分析沙利度胺联合~(125)I粒子植入和单纯~(125)I粒子植入两种方法治疗胰腺癌的疗效。方法 :2012年1月至2014年6月郴州市第一人民医院中心医院肝胆外科的胰腺癌患者33例随机分成A、B组,A组16例,B组17例,其中A组采用沙利度胺联合125I粒子植入治疗,B组采用单纯~(125)I粒子植入治疗。统计学分析对比两组患者的无进展期(PFS),总生存期(OS)。结果 :A组的平均PFS(5.8个月)高于B组的平均PFS(4.3个月)(P<0.05);A组的平均OS(19.1个月)高于B组的平均OS(16.5个月)(P<0.05)。结论 :沙利度胺联合~(125)I粒子植入法与单纯~(125)I粒子植入法相比治疗胰腺癌,沙利度胺联合~(125)I粒子植入法更能延长患者的生存时间,改善患者的生活质量。
Objective: To compare the efficacy of thalidomide combined with 125 I seed implantation and 125 I seed implantation in pancreatic cancer. Methods: From January 2012 to June 2014, 33 patients with pancreatic cancer in the Hepatobiliary Surgery Department of Central Hospital of the First People’s Hospital of Chenzhou City were randomly divided into A and B groups, 16 cases in group A and 17 cases in group B, Degree amine combined with 125I seed implantation, group B with ~ (125) I particle implantation. Statistical analysis was compared between the two groups of patients with no progression (PFS), total survival (OS). Results: The average PFS (5.8 months) in group A was higher than that in group B (4.3 months) (P <0.05). The mean OS in group A (19.1 months) was higher than that in group B Month) (P <0.05). CONCLUSIONS: Thalidomide combined with 125 I seed implantation is superior to 125 I seed implantation in the treatment of pancreatic cancer and thalidomide combined with 125 I seed implantation. The survival time, improve the quality of life of patients.